QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
16 Mai 2022 - 7:30AM
Business Wire
- QIAstat-Dx Rise, which can process up to 56 tests in an
eight-hour shift with enhanced walk-away efficiency, receives
CE-marking to run new respiratory and gastrointestinal
panels
- QIAstat-Dx Respiratory SARS-CoV-2 Panel with CE-marking
expanded to 23 pathogens, now includes Chlamydophila pneumoniae to
detect bacteria that is major cause of respiratory
infections
- QIAstat-Dx Gastrointestinal Panel 2 with CE-marking launched
with expanded pathogen target list and improved sample preparation
and panel performance
- Software upgrade improves cybersecurity, usability and
connectivity features on QIAstat-Dx systems, adding to the
cloud-based connectivity solution QIAsphere
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced the launch of QIAstat-Dx Rise – a high-capacity version
of the QIAstat-Dx automated syndromic system – and enhancements to
the menu of tests for the fully integrated one-step molecular
testing solution that provides results in about one hour.
The launch of QIAstat-Dx Rise comes after the award of European
CE-marking that significantly expands QIAGEN’s offering in
syndromic testing, which is becoming an increasingly important tool
in laboratories settings to test simultaneously for multiple
pathogens from one sample.
“The launch of QIAstat-Dx Rise syndromic testing platform
provides automated, comprehensive pathogen testing for
higher-demand medical institutions,” said Jean-Pascal Viola, Senior
Vice President, Head of the Molecular Diagnostics Business Area at
QIAGEN. “Crucially, QIAstat-Dx Rise is compatible with our updated
QIAstat-Dx Respiratory SARS-CoV-2 Panel, the QIAstat-Dx
Gastrointestinal Panel 2, as well as all of our future assays.”
QIAstat-Dx Rise and its test cartridges are a closed system for
hands-off sample preparation and processing. With a random access
capacity of up to 18 different tests, it can provide diagnostic
results for up to 56 tests in an eight-hour shift and 160 tests per
day by using eight analytical modules. Building on the existing
QIAstat-Dx Analyzer with up to four analytical modules, QIAstat-Dx
Rise is a flexible new option for increased testing capacity.
Among other developments in the QIAstat-Dx portfolio:
- The CE-marked QIAstat-Dx Respiratory SARS-CoV-2 Panel has been
expanded to test for an additional target, Chlamydophila
pneumoniae, a bacteria that is cause of respiratory infections that
can present with influenza-like symptoms. This panel can now be
used to detect and differentiate among 23 viral and bacterial
targets that cause respiratory infections. While C. pneumoniae
typically causes mild illness, it can cause severe outcomes in
high-risk populations, particularly older adults.
- The CE-marked QIAstat-Dx Gastrointestinal Panel 2 has also been
updated with new features for improved sample preparation and panel
performance. This panel can be used to detect and differentiate
among 22 viral, bacterial and parasitic targets that cause
gastrointestinal infections. Importantly, the panel’s STEC target
(Shiga-like toxin E.coli) reports the toxin content (stx1 and
stx2). This information can be used to determine the risk of
certain patient populations to Hemolytic Uremic Syndrome (HUS) and
therefore can help provide the right patient monitoring.
- QIAGEN also released a software upgrade for QIAstat-Dx Analyzer
that enhances the system’s cybersecurity, usability and
connectivity features. The release of software version 1.5.1
enables users to configure their devices to perform mandatory
External Quality Control tests. The new software adds to the
QIAsphere cloud-based connectivity solution that enhances
QIAstat-Dx capabilities in digital diagnostics.
To learn more about QIAGEN’s range of QIAstat-Dx devices and
testing panels, visit QIAGEN.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of March 31,
2022, QIAGEN employed more than 6,000 people in over 35 locations
worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Source: QIAGEN N.V. Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220515005044/en/
QIAGEN: Investor Relations John Gilardi +49 2103
29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer +49 2103 29 11826
e-mail: pr@QIAGEN.com
Qiagen NV (TG:QIA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Qiagen NV (TG:QIA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024